Cooley advised Atara Biotherapeutics, Inc. on its $63 million initial public offering. Atara is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company now trades on The NASDAQ Global Market under the symbol “ATRA.”
Goldman, Sachs & Co. and Citigroup Global Markets Inc. acted as joint book-running managers for the offering, and Jefferies LLC acted as manager for the offering.
The Cooley corporate and securities team advising Atara was comprised of partners Kenneth Guernsey and Jodie Bourdet and associates Carlton Fleming, Robert E. Jones and Eric Cheng.
Critical support was provided by partner Barclay Kamb (life sciences); partner Natasha Leskovsek and associate Bin Wang (health care and life sciences regulatory); partner Bill Christiansen (intellectual property); special counsel Laura McDaniels (compensation and benefits); and partners Susan Cooper Philpot and Bill Morrow (tax).
Related Posts:
- Dermira Prices its Initial Public Offering
- Cooley Advises Portola Pharmaceuticals on its $140 Million IPO
- Invitae Completes $117 Million Initial Public Offering
- Cooley Advises Underwriters on Onconova Therapeutics IPO
- Cooley Advises Xencor on its Initial Public Offering
